To the full analysis
Gan & Lee Pharmaceuticals. stock: growth
603087.SSGan & Lee Pharmaceuticals. reported $605.91M in revenue for fiscal 2025, up 32.7% on the prior year, up 3.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.8%
per year from 2013 to 2025, per share 13.6%
Earnings (Annual rate)
15.4%
per year from 2013 to 2025, per share 13.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 3.7% | 12.7% | 15.8% |
| Revenue per share | 2.6% | 10.9% | 13.6% |
| Earnings | −1.5% | 9.8% | 15.4% |
| Earnings per share | −2.5% | 8.0% | 13.1% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $103.87M | $30.7M | $15.7M |
| 2014 | $138.96M | $45.77M | −$1.54M |
| 2015 | $182.93M | $67.1M | $11.85M |
| 2016 | $265.66M | $115.42M | $76.65M |
| 2017 | $355.49M | $161.96M | $77.77M |
| 2018 | $358.02M | $140.06M | −$14.31M |
| 2019 | $434.16M | $175.05M | $112.07M |
| 2020 | $504.16M | $184.56M | $98.86M |
| 2021 | $541.68M | $217.86M | $57.9M |
| 2022 | $256.78M | −$65.91M | −$102.99M |
| 2023 | $391.11M | $51M | −$66.52M |
| 2024 | $456.69M | $92.18M | $14.47M |
| 2025 | $605.91M | $171.5M | −$21.27M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Jan 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.